Key clinical point: The disease burden of psoriatic arthritis (PsA) was higher in women vs. men even after 1 year of standard-of-care treatment.
Major finding: Women vs. men reported a significantly longer duration of symptoms, higher tender joint count (both P < .05) and enthesitis at baseline ( P < .05), and higher disease activity, higher levels of pain, and a lower functional capacity even after 1 year of follow-up (all P < .05). Minimal disease activity was predominantly present among men vs. women at baseline (18% vs. 10%; P < .05) and at 1 year of follow-up (59% vs. 37%, P < .00).
Study details: This prospective cohort study included 307 men and 313 women newly diagnosed with PsA from the Dutch south-west Early Psoriatic Arthritis Registry (DEPAR), who were followed up for 1 year.
Disclosures: No source of funding was reported for the study . The DEPAR cohort received funding from the Dutch Government, Pfizer, and other sources. The authors declared no conflicts of interest.
Source: Passia E et al. Arthritis Res Ther. 2022;24:22 (Jan 11). Doi: 10.1186/s13075-021-02680-y.